Financhill
Back

Viking Therapeutics Quote, Financials, Valuation and Earnings

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!
Sell
45

VKTX
Viking Therapeutics

Last Price:
63.15
Seasonality Move:
38.04%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Viking Therapeutics Price Quote

$63.15
+0.02 (+-13.35%)
(Updated: November 5, 2024 at 5:46 AM ET)

Viking Therapeutics Key Stats

Sell
45
Viking Therapeutics (VKTX) is a Sell

Day range:
$62.80 - $79.10
52-week range:
$9.34 - $99.41
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
7.72%

Volume:
29M
Avg. volume:
4.1M
1-year change:
498.44%
Market cap:
$7B
Revenue:
$0
EPS:
$-0.93

How Much Does Viking Therapeutics Make?

Data Unavailable

Is Viking Therapeutics Growing As A Company?

Data Unavailable

Viking Therapeutics Stock Price Performance

What Is Viking Therapeutics 52-Week High & Low?

Viking Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Viking Therapeutics?

Is Viking Therapeutics Cash Flow Positive?

  • What Is VKTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$74.2M
  • What Is Viking Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $611.7M
  • What Is Viking Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$524.2M

Viking Therapeutics Return On Invested Capital

Data Unavailable

Viking Therapeutics Earnings Date & Stock Price

Viking Therapeutics Competitors

Viking Therapeutics Dividend Yield

Viking Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 8.12%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 112.85
Upside from Last Price: 78.74%

Major Shareholders

  • How many VKTX shares are owned by institutional investors?
    151.2M VKTX shares are owned by institutional investors
  • How many VKTX shares are owned by insiders?
    4.3M VKTX shares are owned by insiders